News Conference News TCT 2017 Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock Yael L. Maxwell November 09, 2017
News Conference News TCT 2017 Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery Yael L. Maxwell October 31, 2017
News Conference News TCT 2017 TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More Shelley Wood October 20, 2017
News Daily News FDA Expands CoreValve Indication to Include Intermediate-Risk Patients Michael O'Riordan July 10, 2017
News Conference News TVT 2017 Valve Leaflet Thrombosis: Treat It or Leave It Be? Shelley Wood June 19, 2017
News Conference News TVT 2017 Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base Michael O'Riordan June 17, 2017
News Daily News FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement Michael O'Riordan June 06, 2017
News Daily News Conscious Sedation in TAVR Cuts Costs by 25%, Boosts Patient Satisfaction Shelley Wood April 13, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Features Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más Shelley Wood December 30, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular News and Features for 2016 Shelley Wood December 29, 2016
News Opinion Editor's Corner Las Noticias y Blogs Más Populares de TCTMD en 2016 Shelley Wood December 29, 2016
News Daily News Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe Michael O'Riordan September 20, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2016 Caitlin E. Cox September 01, 2016
News Daily News TAVR as an Option for Intermediate-Risk Patients: Physicians Respond Yael L. Maxwell August 24, 2016
News Daily News FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients Yael L. Maxwell August 18, 2016
News Daily News Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients Todd Neale August 01, 2016
News Conference News TVT 2016 Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes Michael O'Riordan June 16, 2016